- INOVIQ (IIQ) enters into a master manufacturing agreement with MP Biomedicals to manufacture the INOVIQ SubB2M protein
- The protein is a key reagent used in SubB2M-based tests to monitor and detect cancer in humans
- Under the agreement, MP Biomedicals will produce the protein in a high-quality current good manufacturing practice grade (cGMP) environment
- MP Biomedicals will also ensure its production process is scalable enough to enable the continued supply of the SubB2M protein for INOVIQ’s diagnostic tests
- IIQ shares are up 3.57 per cent and trading at 58 cents each at 10:59 am AEST
INOVIQ (IIQ) has signed a master manufacturing deal with life science and diagnostic products supplier MP Biomedicals to manufacture the INOVIQ SubB2M-protein.
The protein is a key reagent used in SubB2M-based tests to monitor and detect cancer in humans. Specifically, the protein detects the Neu5Gc pan-cancer biomarker found in multiple human cancers, including breast and ovarian.
Under today’s agreement, MP Biomedicals will produce the SubB2M protein in a high-quality current good manufacturing practice grade (cGMP) environment under an International Organization for Standardization (ISO) quality assurance program.
MP Biomedicals will also ensure its production process is scalable enough to enable the continued supply of the SubB2M protein for INOVIQ’s in-development SubB2m-based diagnostic tests
INOVIQ CEO Leearne Hinch said the agreement was a “key milestone” in securing the commercial supply of the SubB2M protein.
The company holds the exclusive worldwide licence from the University of Adelaide to the SubB2M technology for use in diagnostic applications.
Today’s agreement follows the successful technology transfer of the SubB2M manufacturing and quality control processes from the University of Adelaide to MP Biomedicals for the routine production and testing of the protein for commercial applications.
IIQ shares were up 3.57 per cent and trading at 58 cents each at 10:59 am AEST.